Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04502056
Other study ID # 2029880
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 7, 2020
Est. completion date September 6, 2020

Study information

Verified date July 2021
Source National Bureau of Economic Research, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19. The sample will include African American and white adult Americans and oversample those with less than a college degree.


Description:

Recent data have shown that covid19 is disproportionately infecting and killing African Americans and Latinx people in the United States. Moreover, since our last experiment, the killing of George Floyd by Minnesota police has raised awareness of structural racism in the United States. The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19.The sample will include African American and white adult Americans and oversample those with less than a college degree.


Recruitment information / eligibility

Status Completed
Enrollment 20460
Est. completion date September 6, 2020
Est. primary completion date September 6, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adults who self-identify as African American or white. - an oversample of individuals with less than a college education Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Acknowledgement Racial Injustice AMA
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
African American Sender Acknowledgement
Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
African American Sender in Informational Videos.
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Racial Inequality Highlighted
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
AMA Acknowledgement Drug Pricing
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
White Sender in Acknowledgement
Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
White Sender in Informational Videos
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
No Racial Inequality Highlighting
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Placebo videos
Videos not related to covid-19 will be shown

Locations

Country Name City State
United States JPAL North America Cambridge Massachusetts

Sponsors (5)

Lead Sponsor Collaborator
National Bureau of Economic Research, Inc. Harvard University, Massachusetts General Hospital, Stanford University, Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence Rate for Knowledge Gaps: Control vs. Any Intervention Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10. The outcome was measured immediately following the intervention in the baseline survey.
Primary Incidence Rate for Knowledge Gaps: Control vs. Any Intervention - Follow up Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. Incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10. The outcome was measured at a follow-up within 2 weeks following the intervention
Primary Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention Participants were offered the option of requesting additional information on COVID-19 related resources by clicking on up to five links that included more content. We measured "information seeking behavior" as the number of links for which participants expressed interest, a count variable between 0 (lowest information seeking behavior) and 5 (greatest information seeking behavior). Incidence rate for interest in links is the count of links demanded divided by the maximum possible count: 5. The outcome was measured immediately following the intervention in the baseline survey.
Primary Incidence Rate - Safety Gap Score: Control vs. Any Intervention Participants were asked about how often they engaged in four behaviors of interest: if they wore a mask indoors/outdoors; if they washed their hands; if they followed social distancing guidelines. The safety gap index takes values of 0 (if a participant reported that they always practiced the four behaviors of interest) up to 4 (none). Incidence rate for safety gaps is the count of safety gaps divided by the maximum possible count: 4. The outcome was measured at a follow-up within 2 weeks following the intervention.
Primary Willingness to Pay (WTP) for Masks: Control vs. Any Intervention WTP: the participants will be asked to choose between two masks vs an unrestricted gift card. They will be asked what amount of gift card would make them just as happy to receive two mask versus the gift card. The outcome was measured immediately following the intervention in the baseline survey.
Primary Incidence Rate Ratio (IRR) - Knowledge Gap Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression. The outcome was measured immediately following the intervention in the baseline survey.
Primary Incidence Rate Ratio (IRR) - Knowledge Gap - Follow up Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression. The outcome was measured at a follow-up within 2 weeks following the intervention
Primary Incidence Rate Ratio (IRR) - Information-seeking Behavior Participants were offered the option of requesting additional information on COVID-19 related resources by clicking on up to 5 links that included more content. We measured "information seeking behavior" as the number of links for which participants expressed interest, a count variable between 0 (lowest information seeking behavior) and 5 (greatest information seeking behavior). Incidence rate for interest in links is the count of links demanded divided by the maximum possible count: 5. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression. The outcome was measured immediately following the intervention in the baseline survey.
Primary Incidence Rate Ratio (IRR) - Safety Gap Score Participants were asked about how often they engaged in four behaviors of interest: if they wore a mask indoors/outdoors; if they washed their hands; if they followed social distancing guidelines. The safety gap index takes values of 0 (if a participant reported that they always practiced the four behaviors of interest) up to 4 (none). Incidence rate for safety gaps is the count of safety gaps divided by the maximum possible count: 4. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression. The outcome was measured at a follow-up within 2 weeks following the intervention.
Primary OLS Regression Coefficients - Willingness to Pay (WTP) for Masks WTP: the participants will be asked to choose between two masks vs an unrestricted gift card. They will be asked what amount of gift card would make them just as happy to receive two mask versus the gift card. The regression coefficients compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single ordinary least squares (OLS) regression for WTP masks). The outcome was measured immediately following the intervention in the baseline survey.
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3